Last updated: February 15, 2026
Overview of the Drug and Its Market
NDC 42291-0240 is a proprietary drug marketed under the brand Sivextro, an antibiotic containing tedizolid phosphate. Approved by the FDA in 2014 for the treatment of acute bacterial skin and skin structure infections (ABSSSI), Sivextro belongs to the oxazolidinone class, similar to linezolid.
The drug's indication and efficacy position it as a targeted therapy for resistant gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA). The market for antibiotics targeting resistant gram-positive infections remains significant due to rising antibiotic resistance. However, the market share for Sivextro is impacted by competition from older drugs (linezolid, vancomycin) and newer agents, including televancin and dalbavancin.
Market Size and Current Sales
In 2022, Sivextro reported global sales of approximately $80 million, a decline from peak sales of over $120 million in 2018. The decline reflects increased competition, generic pressure, and changes in prescribing practices favoring oral alternatives with similar efficacy.
The U.S. accounts for roughly 85% of total sales, with the remaining 15% from international markets, primarily Europe and Japan. The major prescriber base includes infectious disease specialists, hospital outpatient clinics, and some outpatient infusion centers.
Competitive Landscape
| Competitor |
Drug Name |
Approved Indication |
Market Share (2022) |
Price Positioning |
| Pfizer |
Zyvox (linezolid) |
ABSSSI, pneumonia |
50% |
Slightly lower than Sivextro for inpatient settings |
| Melinta Therapeutics |
Baxdela (delafloxacin) |
ABSSSI, respiratory infections |
20% |
Similar or slightly lower pricing |
| FDA-approved generics |
None (patent protected) |
N/A |
0% (patent protected) |
N/A |
| Other agents |
Dalvance (dalbavancin), Vancocin (vancomycin) |
N/A |
15-20% |
Varies, often lower in outpatient settings |
The market is consolidating, with only a few drugs capturing large segments. Sivextro maintains a niche, mostly in resistant infections where oral options are limited.
Pricing Analysis and Projections
In 2022, the average wholesale price (AWP) for Sivextro was approximately $150 per 200 mg tablet, with treatment courses typically running 6-10 days. The average course cost is estimated at $900 to $1,500.
Factors Affecting Price Changes
- Market Competition: Introduction of generic products (notably linezolid, though patent expiry for Sivextro is in 2029) pressures pricing.
- Patent Expiration and Exclusivity: Patent is set to expire in 2029, likely leading to generic entry afterward, significantly reducing prices.
- Formulation and Administration: IV formulations dominate the market; oral bioavailability limits substitution with oral-only drugs.
Projected Price Trajectory (2023-2027)
| Year |
Estimated AWPs |
Commentary |
| 2023 |
$140 - $150 |
Stability due to branded status, limited generic competition yet |
| 2024 |
$130 - $145 |
Slight decline anticipated with increased generic influence |
| 2025 |
$120 - $140 |
Continued downward pressure, with some market share erosion |
| 2026 |
$110 - $130 |
Entry of generics (post-2029 patent expiry likely accelerated) |
| 2027 |
$100 - $125 |
Further depreciation, with a focus on hospital pricing strategies |
Pricing Strategies and Market Penetration
Pharmaceutical companies generally favor volume-based sales through hospital contracts and insurance negotiations. Future pricing strategies may include discounts, bundled offerings, or value-based pricing models to maintain competitiveness.
Regulatory and Policy Impact
Policy shifts aimed at reducing antibiotic overuse, especially in outpatient settings, could influence prescribing patterns and consequently impact pricing and sales.
Key Takeaways
- NDC 42291-0240 (Sivextro) is situated within a competitive antibiotic market focused on resistant gram-positive infections.
- Sales have declined from peak levels, with a 2022 global figure of approximately $80 million.
- The drug's pricing currently hovers around $150 per course, with projections indicating a decline toward $100 by 2027, largely due to generic entry after patent expiration.
- Market share will depend on off-patent competition, formulary inclusion, and shifts toward oral or novel antibiotics.
- Entry of generics in 2029 will likely yield substantial price erosion, with long-term forecasts favoring commoditized pricing levels.
FAQs
1. When is the patent for Sivextro set to expire?
Patent protection is expected to expire in 2029, opening the market to generic competition.
2. What factors could accelerate the decline in Sivextro’s price?
Introduction of generics post-2029, policy changes reducing inpatient antibiotic usage, and increased use of oral substitutes could accelerate price declines.
3. How does Sivextro compare legally and clinically to linezolid?
Clinically, Sivextro has similar efficacy with a different side-effect profile and dosing schedule. Patent exclusivity prolongs market monopoly, keeping prices higher until 2029.
4. Which markets could see growth in Sivextro’s sales?
Emerging markets with rising resistance levels and limited access to newer antibiotics may drive growth, provided regulatory and reimbursement structures support use.
5. What are the key factors influencing future pricing strategies for Sivextro?
Market competition, patent expiry, insurance negotiations, hospital formulary preferences, and development of next-generation antibiotics will influence pricing strategies.
References
[1] U.S. FDA. Sivextro (tedizolid phosphate) FDA approval details. 2014.
[2] IQVIA. 2022 Worldwide Review of Antibiotic Sales.
[3] EvaluatePharma. 2022 Market Intelligence Report.
[4] Bloomberg Intelligence. Antibiotics Market Analysis. 2022.
